EndtheFed1776 Wednesday, 08/19/15 08:10:19 PM Re: None Post # of 135 OCAT the next REGN OCAT just raised cash today in a very creative non-dilutative financing. They are about to start an efficacy trial for dry age-related macular degeneration (AMD) and a pivotal trial for Stargardt's macular degeneration (SMD). The stock was up 12% today. OCAT only has 40 million shares outstanding, and a market cap of only $150 million. Once they confirm the efficacy they saw in the P1 trial, this stock is going to $300 plus. The market, as REGN investors know, for AMD is HUGE! Time to take some profits off the table here and invest them in OCAT, in my humble opinion. I see OCAT as being the next REGN and then some.